NEO
NeoGenomics Inc
19.60$
+6.5%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 35.0% | 35.5% | 35.0% | 35.6% | 36.0% | 36.4% | 35.8% | 28.1% | 27.8% | 27.7% | 27.8% | 28.2% | |
| 18.2% | 20.4% | 20.2% | 21.6% | 22.1% | 22.4% | 21.6% | 11.1% | 11.9% | 11.7% | 10.9% | 10.8% | |
| 24.0% | 24.7% | 23.5% | 23.6% | 23.6% | 23.6% | 22.4% | 11.7% | 11.9% | 11.7% | 10.9% | 10.8% | |
| 7.9% | 7.8% | 8.7% | 8.9% | 9.2% | 9.2% | 9.4% | 11.0% | 11.3% | 11.7% | 12.4% | 13.0% | |
| 1.4% | 1.4% | 1.2% | 1.4% | 1.5% | 1.6% | 1.9% | 2.5% | 2.1% | 2.1% | 2.2% | 2.0% | |
| 31.1% | 31.1% | 31.9% | 31.8% | 31.9% | 31.9% | 32.6% | 37.6% | 38.1% | 38.6% | 38.9% | 38.8% | |
| 22.8% | 22.2% | 22.2% | 21.7% | 21.2% | 20.7% | 20.7% | 21.7% | 21.4% | 21.1% | 20.7% | 20.1% | |
| 43.5% | 44.0% | 43.7% | 44.3% | 44.7% | 44.9% | 44.5% | 38.7% | 39.0% | 38.5% | 38.5% | 41.8% | |
| 5.5% | 5.7% | 4.7% | 17.6% | 18.1% | 18.4% | 17.5% | 7.2% | 7.1% | 6.5% | 6.3% | 7.8% | |
| 0.4% | 0.3% | 0.3% | 12.4% | 12.4% | 12.5% | 12.8% | 0.3% | 0.3% | 0.4% | 0.4% | 0.4% | |
| 1.0% | 1.2% | 1.1% | 1.0% | 1.0% | 1.3% | 1.0% | 2.0% | 1.6% | 1.7% | 1.9% | 7.4% | |
| 32.0% | 32.0% | 32.9% | 20.7% | 20.7% | 20.8% | 21.3% | 24.5% | 24.8% | 25.1% | 25.4% | 27.7% | |
| 56.5% | 56.0% | 56.3% | 55.7% | 55.3% | 55.1% | 55.5% | 61.3% | 61.0% | 61.5% | 61.5% | 58.1% | |
| -13.9% | -14.7% | -16.7% | -17.8% | -18.9% | -19.9% | -22.0% | -28.5% | -30.8% | -31.9% | -33.5% | -33.2% | |
| 1.5% | 1.5% | 1.5% | 1.5% | 1.5% | 1.5% | 1.6% | 1.8% | 1.9% | 1.9% | 1.9% | 1.9% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.